Blood Pressure Control Measures and Cardiovascular Outcomes: a Prospective Hypertensive Cohort
Overview
Authors
Affiliations
Purpose: We investigated whether blood pressure (BP) control measures, visit-to-visit BP variability, and time in therapeutic range (TTR) are associated with future cardiovascular outcomes in hypertensive patients.
Materials And Methods: Among 1,408 hypertensive patients without cardiovascular disease, we prospectively evaluated the incident major cardiovascular events over 6 years. In newly diagnosed patients, antihypertensive drug treatment was initiated. We estimated two markers of on-treatment BP control, (1) visit-to-visit BPV as the coefficient of variation of office systolic BP (BP-CV), and (2) TTR calculated as the percentage of office systolic BP measurements within 120-140mmHg across visits.
Results: The hypertensive cohort (672 males, mean age 60 years, 31% newly diagnosed) had a mean systolic/diastolic BP of 142/87 mmHg. The mean number of visits was 4.9 ± 2.6, while the mean attained systolic/diastolic BP during follow-up was 137/79 mmHg using 2.7 ± 1.1 antihypertensive drugs. The BP-CV and TTR were 9.1 ± 4.1% and 45 ± 29%, respectively, and the incidence of the composite outcome was 8.3% ( = 117). After adjustment for relevant confounders and standardization to z-scores, BP-CV and TTR were associated with a 43% (95% CI, 27-62%) increase and a 33% (95% CI, 15-47%) reduction in the outcome. However, the joint evaluation of TTR and BP-CV in a common multivariable model indicated that a standardized change of TTR was associated with the outcome to a greater extent than BP-CV (mean hazard ratios of 30% vs. 24%, respectively). When combined with the higher BP standardized-CV quartile, the lower TTR quartile predicted the outcome by 2.3 times (95% CI, 1.1-5.4) compared to the inverse TTR and BP-CV quartile pattern.
Conclusion: High BP-CV or low TTR was associated with future cardiovascular events in a cohort of treated hypertensive patients. As a determinant, the extent of TTR value appears greater than BP-CV when these measures are considered in the same multivariable model.
Otsuka Y, Ishii M, Ikebe S, Nakamura T, Tsujita K, Matoba T Open Heart. 2024; 11(2.
PMID: 39719275 PMC: 11667424. DOI: 10.1136/openhrt-2024-002987.
Kario K, Kanegae H, Hoshide S Hypertens Res. 2024; 48(2):604-612.
PMID: 39394518 DOI: 10.1038/s41440-024-01940-z.
Li W, Gnanenthiran S, Schutte A, Tan I Hypertens Res. 2024; 47(9):2337-2350.
PMID: 39014114 PMC: 11374670. DOI: 10.1038/s41440-024-01798-1.
Kario K, Tomitani N, Okawara Y, Kanegae H, Hoshide S Hypertens Res. 2023; 47(1):112-119.
PMID: 37714954 DOI: 10.1038/s41440-023-01416-6.